Goldman Sachs
JUNO

Goldman Sachs’s Juno Therapeutics, Inc. JUNO Stock Holding History

Goldman Sachs’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,594,770
Closed -$72.9M – 6661
2017
Q4 		$72.9M Buy
1,594,770
+674,093
+73% +$33.6M 0.02% 1005
2017
Q3 		$41.3M Buy
920,677
+53,296
+6% +$1.82M 0.01% 1428
2017
Q2 		$25.9M Buy
867,381
+7,521
+0.9% +$186K 0.01% 1731
2017
Q1 		$19.1M Buy
859,860
+711,209
+478% +$15.3M 0.01% 1916
2016
Q4 		$2.8M Sell
148,651
-165,514
-53% -$4.05M ﹤0.01% 3534
2016
Q3 		$9.43M Sell
314,165
-16,258
-5% -$506K ﹤0.01% 2502
2016
Q2 		$12.7M Buy
330,423
+224,545
+212% +$9.32M ﹤0.01% 2127
2016
Q1 		$4.03M Sell
105,878
-228,410
-68% -$7.96M ﹤0.01% 2875
2015
Q4 		$14.7M Buy
334,288
+193,502
+137% +$9.6M ﹤0.01% 1974
2015
Q3 		$5.73M Buy
140,786
+125,706
+834% +$5.51M ﹤0.01% 2767
2015
Q2 		$804K Sell
15,080
-1,981
-12% -$105K ﹤0.01% 4731
2015
Q1 		$1.03M Buy
+17,061
New +$828K ﹤0.01% 4439

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Goldman Sachs's JUNO Position: Q1 2018 in Review

Goldman Sachs sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,594,770 shares — an estimated $72.9M sold.

Goldman Sachs first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $72.9M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Goldman Sachs reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Goldman Sachs sold 1,594,770 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $72.9M.
  • Goldman Sachs first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • Goldman Sachs's Juno Therapeutics, Inc. position peaked at $72.9M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.